GlobalData has released its new
Country report, PharmaPoint: Osteoporosis India Drug Forecast and Market
Analysis to 2022. Despite its maturity, the osteoporosis market is expected to
undergo substantial change between 2012 and 2022. Most importantly, the gold-standard
bisphosphonates will lose patent protection by end-of-year 2013, flooding the
marketplace with less expensive generic versions of these physician-preferred
medications. Additionally, Eli Lillys blockbuster Evista, the only available
SERM in the US, will lose patent protection in 2014, flooding the market with
yet more affordable generic options. Also during the forecast period covered by
this report, osteoporosis drug development research will lead to the launches
of a wave of novel anabolic drugs with greater efficacy and safety, causing a
major market shift away from anti-resorptive drugs. The number of companies
vying for patient share will shrink by as much as 50%, as established players
exit the market or acquire smaller players. Lastly, the aging of the population
in developed markets will result in a larger patient pool.
These changes in the osteoporosis
market will be reflected in the slow growth during the forecast period, with
the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/pharmapoint-osteoporosis-india-drug-forecast-and-market-analysis-to-2022
The recession will be caused by
floods of generic products into the market. India has always had loose IP
rights, requiring significant efficacy improvements in order for a drug to gain
protection. However, as of 2012, India will start issuing compulsory licenses
for Indian generics companies to violate IP and produce drugs prior to patent
expiries. Therefore, GlobalData expects the Indian market to be dominated by
generic products, and to lose significant value in the branded side of the drug
market. For this reason, GlobalData did not project the pipeline products
launching in the major markets because sales will likely be retarded by generic
products.
Scope
- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Osteoporosis market.
To
Buy The Copy of This Report Visit:
http://www.marketresearchreports.biz/analysis/165865
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India
.
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
No comments:
Post a Comment